Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BWAY
BWAY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BWAY News
Wall Street Analysts Adjust Ratings on Key Stocks
Jan 26 2026
Benzinga
BrainsWay Secures Expanded Coverage for Depression Treatment from Highmark
Jan 21 2026
Globenewswire
BrainsWay (BWAY) Receives FDA Approval for Proliv™Rx System for Depression Treatment
Jan 12 2026
Globenewswire
BrainsWay to Host Virtual Analyst & Investor Day on December 1, 2025
Nov 25 2025
Newsfilter
BrainsWay Obtains FDA Approval for Deep TMS™ as Additional Treatment for Major Depressive Disorder in Teens Aged 15 to 21
Nov 13 2025
Newsfilter
Northland Capital Markets Reaffirms Outperform Rating for BrainsWay, Increases Price Target to $23
Nov 12 2025
Benzinga
Earnings Report Ahead of Market Opening for November 11, 2025: SE, AU, PVLA, DAVA, BWAY, CRNT, PODC, ACCS, WKHS
Nov 10 2025
NASDAQ.COM
BrainsWay Invests in Two Minority Stakes in U.S. Mental Health Providers
Oct 27 2025
NASDAQ.COM
BrainsWay Soars Following FDA Approval of Accelerated Deep TMS Protocol
Sep 16 2025
SeekingAlpha
BWAY Stock Increases Following Strategic Investment in Neurolief's Home Care Solutions
Aug 22 2025
NASDAQ.COM
BrainsWay Aims to Broaden Its Market Reach with Strategic Investment in Neuromodulation Systems Firm Neurolief Ltd.
Aug 21 2025
Newsfilter
BrainsWay Purchases Minority Stake in Axis Integrated Mental Health
Aug 20 2025
Newsfilter
Rising Earnings Projections Indicate Potential Growth for Brainsway (BWAY) Stock
Aug 18 2025
NASDAQ.COM
Breaking Down BrainsWay: 4 Analysts Share Their Views
Aug 14 2025
Benzinga
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target
Jun 12 2025
Benzinga
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
Jun 11 2025
Newsfilter
Show More News
